基本信息:62岁女性,HPV42,TCTHSIL,绝经后阴道流血10天来我院就诊。妇科检查:宫颈表面出血,轮廓欠清晰。三合诊:双侧骶主韧带未及增粗。宫颈活检:腺癌。PET/MR提示:宫颈上段不规则增厚FDG代谢增高,考虑宫颈恶性肿瘤并累及子宫体下段;宫腔积液(血),余未见明显FDG代谢增高肿瘤性病变。治疗过程:完善检查后予行腹式广泛全子宫+双附件切除+盆腔淋巴结清扫+腹主动脉旁淋巴结切除术。术中见宫颈部质硬增粗,肿瘤直径约3.5cm,侵犯阴道上1/3处(阴道侧穹窿均累及)。术后剖视离体标本:侧穹窿均消失,宫颈管内见一直径约3.5cm肿瘤组织凸向浆膜层,质地韧给,阴道残端距离病灶约2.5cm,宫旁约3cm。术后病理:宫颈浸润性腺癌。肿瘤所在位置:宫颈;肿瘤大体类型:内生性;肿瘤大小:4×1.7×1.8cm(长径×横径×纵径cm);组织学类型:宫颈腺癌(endocervicaladenocarcinoma);淋巴结转移:总数:(2/49)(转移数/淋巴结总数);左髂总:(0/4);左髂内:(0/6);左髂外:(0/6);左闭孔:(0/8);左腹股沟深:(0/3);右髂总:(0/4);右髂内:(1/1);右髂外:纤维脂肪组织;右闭孔:(0/14);右腹股沟深:脂肪组织;右腹主动脉旁:(1/3);组织学分化:中-低分化;浸润深度:宫颈纤维肌壁全层;免疫组化结果:CK5/6(-),CK(+),ER(-),PR(-),Ki-67(70%,+),P53(+),P16(-),P40(-),CEA(+),PAX-8(+),Vim(-)。PD-1(淋巴细胞+,约10%),PD-L1(CPS约1,克隆号E1L3N)。患者最终诊断:宫颈腺癌ⅢC1期(T2a1N2M0期PS评分0分KPS评分100分)子宫颈腺癌基本概念:宫颈腺癌是一种腺体形成性肿瘤,通常起源于子宫颈转化区,表现为基质浸润和/或扩张型浸润。从外观上看,宫颈腺癌可能表现为溃疡、外生性肿块,或者在内生性生长时表现为桶状宫颈。子宫颈腺癌可与hpv相关(最常见的是HR-HPV18、16和45型),与HPV无关的腺癌相比,HPV相关的宫颈腺癌表现出更好的临床预后,因此建议检测HPV感染状态。组织学亚型:-HPV相关腺癌:包括常见类型,约占病例的75%,包括绒毛腺亚型和微乳头亚型和黏液型。包括肠癌、印戒细胞癌和浸润性分层粘液分泌癌。-与HPV无关的宫颈内膜腺癌:包括胃型腺癌、透明细胞癌、间质细胞癌和子宫内膜样癌。鉴别:利用免疫组化染色(vim、ER、p16和单克隆CEA)可有助于区分宫颈内膜癌和子宫内膜癌。通常情况下,子宫内膜样腺癌会表达vim和ER,而宫颈内膜腺癌则是mCEA和p16阳性表达(HPV相关)。治疗方案:同宫颈鳞癌。低风险早期子宫颈癌即经锥切确诊的IA2~IB1期并满足以下条件:无淋巴脉管间隙浸润(LVSI)、切缘阴性、鳞癌(任何级别)或普通类型腺癌(仅G1或G2)、肿瘤直径s2cm、浸润深度≤10mm、影像学检查无其他部位转移者,可采用锥切术或单纯子宫切除术联合双侧盆腔淋巴结切除术或加前哨淋巴结活检。一项前瞻性随机试验表明,微创根治性子宫切除术的无病生存率(DFS)和总生存率低于腹部切开根治性子宫切除术。对于子宫切除术后出现阴性淋巴结、阴性切缘、阴性宫旁、无宫颈高危险因素的患者,可进行观察。然而,如果发现病理危险因素,则需要在根治性子宫切除术后进行辅助治疗。总结:子宫颈腺癌是一种起源于转化区的腺体形成性肿瘤,最常见的为HPV18感染类型,与HPV无关的腺癌相比,HPV相关的宫颈腺癌表现出更好的临床预后。据相关报道,HPV42虽然被认为是一种非致癌的"低危"HPV,它却再现了致癌的"高危"HPV的分子特征。 参考资料:1.《NCCN宫颈癌指南》1.2024版2.LeiendeckerL,NeumannT,JungPS,etal.HumanPapillomavirus42DrivesDigitalPapillaryAdenocarcinomaandElicitsaGermCell-likeProgramConservedinHPV-PositiveCancers.CancerDiscov.2023;13(1):70-84.doi:10.1158/2159-8290.CD-22-0489本文所有图片选自网络临床主攻妇科肿瘤微创/开腹手术和综合治疗。宫颈癌前病变/宫颈癌诊治。腹腔镜、单孔腹腔镜、宫腔镜。专家门诊时间周一全天、周二上午周四上午妇科专家特需门诊地址:上海市浦东新区即墨路150号,上海市东方医院北院。周二下午妇科专家门诊,地址:上海市浦东新区云台路1800号,上海市东方医院南院周四下午线上门诊。科室介绍上海市东方医院(同济大学附属东方医院)本部妇科设有普通妇科、宫颈疾病、妇科肿瘤、盆底重建、生殖外科、计划生育和妇科内镜。妇科以“创建诊疗特色鲜明的临床研究复合型学科”为目标,在医、教、研各方面实现跨越式发展,各亚专科逐渐形成明显特色。科室始终坚持以人为本,重点培养中青年技术骨干,增强团队的整体技术能力,优化医疗环境,提高医疗质量。开展新技术、新项目,倡导微笑服务,不断焕发新的活力,在竞争中发展壮大。科室技术力量雄厚,拥有4K荧光腹腔镜、3D腹腔镜、wolf宫腔镜、莱斯康4K阴道镜,显微内镜等国际一流的现代化手术设备,进行各类妇科手术诊治。在妇科良、恶性肿瘤诊断、手术和综合治疗方面积累了丰富的临床经验。在妇科微创手术、腹腔镜/单孔腹腔镜/经阴道单孔腹腔镜、盆底重建、妇科肿瘤保留子宫和生育功能手术、射频消融治疗子宫肌瘤等方面具有鲜明的学科特色。宫颈癌前病变及宫颈癌诊疗水平居国际领先地位。目前妇科门诊:开设了宫颈疾病、普通妇科门诊、宫腔镜门诊,计划生育门诊,妇科肿瘤门诊。门诊开展阴道镜以及显微阴道镜检查,leep术,宫腔镜检查,无痛人流以及各类计划生育手术。01周边交通02公交线路01路82路 119路 455路 522路 607路 630路 792路 798路 799路 818路 981路 992路 隧道三线 314路 隧道夜宵线 陆家嘴金融城2路 陆家嘴金融城3路 钦东专线 上川专线 新川专线(公交车站距离东方100米之内)03地铁线路4号线浦东南路站3号出口3A号口:正门-急诊、门诊、儿科3B号口:西门-新大楼(特需、病房)2号线东昌路站(出站步行约10分钟)4号线浦东大道站或换乘14号线到浦东南路站9号线商城路站科研介绍李芳主任团队开展临床和临床相关基础研究。同济大学附属东方医院本部妇科是妇科学博士后和硕博士研究生培养点,医师规范化培训基地。主要研究方向:高危HPV整合相关致癌机制、三代转录组和宫单细胞测序揭示宫颈癌免疫微环境和宫颈癌免疫治疗新靶点。李芳教授以通讯作者身份在NucleicAcidsResearch,JExpClinCancerRes.等期刊上发表40余篇学术论文。累计影响因子251.4分,最高影响因子20.69分。主持国家自然基金、科技部重大项目、上海市科委、卫健委和上海市申康课题20余项。主编论著2部。获省部二等奖1项(2/7)。国家级宫颈病专业精英奖1项。获批发明专利3项,实用新型专利5项。知识产权转化1项:显微内镜在体病理诊断子宫颈病变。实验室依托同济大学附属东方医院转化医学研究中心,拥有具有完成国家级科研项目所必需的先进仪器设备和充足的科研经费您还可以扫码与我们联系~
近年来,随着宫颈癌筛查的普及以及诊治水平的提高,虽然宫颈癌的发病率在发达国家呈现下降趋势,但是85%的病例都发生于发展中国家。目前在我国,宫颈癌的发病率呈现上升趋势和年轻化趋势。罹患宫颈癌同时又有生育愿望的女性所占比例正在逐渐加大。有报道表示我国35岁以下宫颈癌患者从上世纪80年代的占比5%以下已经上升到本世纪初的30%或更高[1,2]。由此可见对于符合条件且有生育愿望的早期宫颈癌患者,在不影响肿瘤治疗效果的前提下,保留患者的生育功能对其身心健康和社会和谐发展都至关重要。虽然目前宫颈癌保留生育功能的治疗方法已日渐成熟,但是对其适应症的把握和治疗方式的质量把握还有待进一步达成共识统一。于是本推送重点解读2022版中国临床肿瘤学会(CSCO)宫颈癌诊疗指南[3]关于宫颈癌保留生育手术相关内容。一.适应症(1)FIGO分期:(I级推荐)IA1-IB2期;(2)病理类型:(I级推荐)宫颈鳞癌、腺癌和腺鳞癌,排除神经内分泌癌、胃型腺癌;(II级推荐)透明细胞癌,腺肉瘤,胚胎横纹肌肉瘤(3)影响评估:(I级推荐)肿瘤局限于宫颈,病灶未侵犯宫颈内口,无淋巴结转移;(4)生育力评估:(I级推荐)年龄=<45岁,有强烈的生育愿望,无明确生育功能障碍;二.诊断及术前评估(1)诊断:(I级推荐)妇科检查+宫颈活检;(2)分期诊断:(I级推荐)胸部CT+腹部增强CT+喷泉增强MRI或PET/CT;(II级推荐)胸部、腹部、盆腔CT;(3)生育能力评估:(I级推荐)抗苗勒氏激素(AMH)或窦卵泡计数a;(II级推荐)年龄=<45岁,性激素检查b;注释:a:为了更好地评估患者术前卵巢储备功能,建议在月经周期任意时期进行AMH激素检查,或月经第1-3天通过超声检查双侧卵巢窦卵泡计数;b:性激素检查包括卵泡刺激素、黄体生成素、雌二醇、孕酮、睾酮以及泌乳素,可于月经期第1-3天(卵泡期)抽血检查;三.治疗(1)IA1,LVSI(-):(I级推荐)宫颈锥切或LEEP刀a;(2)IA1,LVSI(+)/IA2:(I级推荐)根治性宫颈切除术b,e+盆腔淋巴结切除术(前哨淋巴结活检术),或宫颈锥切术a+盆腔淋巴结切除术(前哨淋巴结活检术);(3)IB1:(I级推荐)腹式或阴式攻根治性宫颈切除术b,f+盆腔淋巴结切除术(前哨淋巴结活检术);(II级推荐)腹腔镜或机器人根治性宫颈切除术b,d,f+盆腔淋巴结切除术(前哨淋巴结活检术);(4)IB2:(I级推荐)腹式根治性宫颈切除术c,g+盆腔淋巴结切除术;(III级推荐)新辅助化疗+根治性宫颈切除术或宫颈锥切术h;注释:a:至少保证3mm阴性宫颈切缘;b:至少保证5-8mm阴性宫颈切缘;c:至少保证8-10mm阴性宫颈切缘;d:经过锥切且切缘阴性需补充手术的患者,实施腹腔镜或机器人根治性宫颈切除术更为安全;e:相当于Q-MB型根治术的切除范围;f:相当于Q-MB型或C1型根治术的切除范围;g:相当于Q-MC1-C2型根治术的切除范围;h:盆腔淋巴结切除可在新辅助化疗前或新辅助化疗后实施,需确保盆腔淋巴结病理阴性才可实施保育手术;参考文献:1.Chan,Y.Y.,etal.,Theprevalenceofcongenitaluterineanomaliesinunselectedandhigh-riskpopulations:asystematicreview.HumanReproductionUpdate,2011.17(6):p.761-771.2.Letterie,G.S.,Managementofcongenitaluterineabnormalities.ReproductiveBiomedicineOnline,2011.23(1):p.40-52.3.中国临床肿瘤学会(CSCO)宫颈癌诊疗指南.2022科室介绍上海市东方医院(同济大学附属东方医院)本部妇科设有普通妇科、宫颈疾病、妇科肿瘤、盆底重建、生殖外科、计划生育和妇科内镜。妇科以“创建诊疗特色鲜明的临床研究复合型学科”为目标,在医、教、研各方面实现跨越式发展,各亚专科逐渐形成明显特色。科室始终坚持以人为本,重点培养中青年技术骨干,增强团队的整体技术能力,优化医疗环境,提高医疗质量。开展新技术、新项目,倡导微笑服务,不断焕发新的活力,在竞争中发展壮大。科室技术力量雄厚,拥有4K荧光腹腔镜、3D腹腔镜、wolf宫腔镜、莱斯康4K阴道镜,显微内镜等国际一流的现代化手术设备,进行各类妇科手术诊治。在妇科良、恶性肿瘤诊断、手术和综合治疗方面积累了丰富的临床经验。在妇科微创手术、腹腔镜/单孔腹腔镜/经阴道单孔腹腔镜、盆底重建、妇科肿瘤保留子宫和生育功能手术、射频消融治疗子宫肌瘤等方面具有鲜明的学科特色。宫颈癌前病变及宫颈癌诊疗水平居国际领先地位。目前妇科门诊:开设了宫颈疾病、普通妇科门诊、宫腔镜门诊,计划生育门诊,妇科肿瘤门诊。门诊开展阴道镜以及显微阴道镜检查,leep术,宫腔镜检查,无痛人流以及各类计划生育手术。本部(北院)周边交通公交线路01路82路119路455路522路607路630路792路798路799路818路981路992路隧道三线314路隧道夜宵线陆家嘴金融城2路陆家嘴金融城3路钦东专线上川专线新川专线(公交车站距离东方100米之内)地铁线路4号线浦东南路站3号出口3A号口:正门-急诊、门诊、儿科3B号口:西门-新大楼(特需、病房)2号线东昌路站(出站步行约10分钟)4号线浦东大道站或换乘14号线到浦东南路站9号线商城路站李芳主任团队开展临床和临床相关基础研究。同济大学附属东方医院本部妇科是妇科学博士后和硕博士研究生培养点,医师规范化培训基地。主要研究方向:高危HPV整合相关致癌机制、三代转录组和宫单细胞测序揭示宫颈癌免疫微环境和宫颈癌免疫治疗新靶点。李芳教授以通讯作者身份在NucleicAcidsResearch,JExpClinCancerRes.等期刊上发表40余篇学术论文。累计影响因子251.4分,最高影响因子20.69分。主持国家自然基金、科技部重大项目、上海市科委、卫健委和上海市申康课题20余项。主编论著2部。获省部二等奖1项(2/7)。国家级宫颈病专业精英奖1项。获批发明专利3项,实用新型专利5项。知识产权转化1项:显微内镜在体病理诊断子宫颈病变。实验室依托同济大学附属东方医院转化医学研究中心,拥有具有完成国家级科研项目所必需的先进仪器设备和充足的科研经费。发表论文如下:1.MinLiu#,ZhiqiangHan#,YongZhi,YetianRuan,GuangxuCao,GuangxueWang,XinxinXu,JianbingMu,JiuhongKang,FangpingDai,XuejunWen,QingfengZhang,FangLi.Long-readsequencingrevealsoncogenicmechanismofHPV-humanfusiontranscriptsincervicalcancer.TranslationalResearch.(IF=10.17)2.ZhiY,ChenX,CaoG,ChenF,SeoHS,LiF.TheeffectsofairpollutantsexposureonthetransmissionandseverityofinvasiveinfectioncausedbyanopportunisticpathogenStreptococcuspyogenes.EnvironPollut.2022Oct1;310:119826.IF=9.983.HuH,YangM,DongW,YinB,DingJ,HuangB,ZhengQ,LiF,HanL.APyroptosis-RelatedGenePanelforPredictingthePrognosisandImmuneMicroenvironmentofCervicalCancer.FrontOncol.2022Apr29;12:873725.IF=5.74.JianyiD,HailiG,BoY,MeiqinY,BaoyouH,HaoranH,FangL,QingliangZ,LingfeiH.Myeloid-derivedsuppressorcellscross-talkwithB10cellsbyBAFF/BAFF-Rpathwaytopromoteimmunosuppressionincervicalcancer.CancerImmunolImmunother.2022Jun20.IF=6.35.Yang,M.#,Hu,H.#,Wu,S.,Ding,J.,Yin,B.,Huang,B.,Li,F.,Guo,X.,&Han,L.(2022).EIF4A3-regulatedcirc_0087429canreverseEMTandinhibittheprogressionofcervicalcancerviamiR-5003-3p-dependentupregulationofOGNexpression.Journalofexperimental&clinicalcancerresearch:CR,41(1),165.IF=12.666.YinBo#,DingJianyi#,HuHaoran#,YangMeiqin,HuangBaoyou,DongWei,LiFang,HanLingfei.OverexpressedCMTM6improvesprognosisandassociatedwithimmuneinfiltratesofovariancancer.FrontMolBiosci.2021.IF=6.117.LeFu#,WeiXia#,WeiShi,GuangxuCao,YetianRuana,XingyuZhao,MinLiu,SumeiNiu,FangLi,XinGao.Deeplearningbasedcervicalscreeningbythecross-modalintegrationofcolposcopy,cytology,andHPVtest.InternationalJournalofMedicalInformatics,159(2022)104675.IF=4.738.XinxinXu#,ZhiqiangHan#,YetianRuan,MinLiu,GuangxuCao,ChaoLi,FangLi.HPV16-LINC00393integrationalterslocal3Dgenomearchitectureincervicalcancercells.FrontCellInfectMicrobiol.2021Dec7;11:785169.IF=6.079.ZhiyuanHuang#,FangLi,QinchuanLi.ExpressionprofileofRNAbindingproteinincervicalcancerusingbioinformaticsapproach.CancerCellInt.2021Dec4;21(1):647.IF=6.4210.LiY#,GongYX#,WangQ,GaoS,ZhangH,XieF,CongQ,ChenL,ZhouQ,HongZ,QiuL,LiF,XieY,SuiL.OptimizingtheDetectionofOccultCervicalCancer:AProspectiveMulticentreStudyinChina.IntJWomensHealth.2021Oct27;13:1005-1015.IF=2.5911.ZhuJ#,ChenF,LuoL,WuW,DaiJ,ZhongJ,LinX,ChaiC,DingP,LiangL,WangS,DingX,ChenY,WangH,QiuJ,WangF,SunC,ZengY,FangJ,JiangX,LiuP,TangG,QiuX,ZhangX,RuanY,JiangS,LiJ,ZhuS,XuX,LiF,LiuZ,CaoG,ChenD.Single-cellatlasofdomesticpigcerebralcortexandhypothalamus.ScienceBulletin2021,66(14):1448-1461.IF=20.5712.RuanY#,LiuM,GuoJ,ZhaoJ,NiuS,LiFang,Evaluationoftheaccuracyofcolposcopyindetectinghigh-gradesquamousintraepitheliallesionandcervicalcancer.ArchGynecolObstet.2020Aug;10.1007/s00404-020-05740-x.doi:10.1007/s00404-020-05740-xIF=2.4913.Guo,Junhan#,FuLe#,ZhaoJunwei,LeiLei,ZhanQin,LiuMin,RuanYetian,LiHui,XuJin,LiNana,WangHanlin,ZhuHuiting,HanZhiqiang,LiFang,Thevalueofmicroendoscopyinthediagnosisofcervicalprecancerouslesionsandcervicalmicroinvasivecarcinoma.ArchivesofGynecologyandObstetrics.2020June302.doi:10.1007/s00404-020-05565-8.IF=2.4914.WenYu#,CaiLong,TailinZhu,HuitingZhu,ZhiqiangHan,FangLi,Highresolutionmultispectralendoscopysignificantlyimprovesthediagnosticaccuracyofcervicalintraepitheliallesions.Journalofobstetricsandgynaecologyresearch,2020April,46:939-944.doi:10.1111/jog.14241.IF=1.6915.ChaoLi#,HongfengAo#,GuofangChen,FangWang,FangLi.TheInteractionofCDH20Withβ-CateninInhibitsCervicalCancerCellMigrationandInvasionviaTGF-β/Smad/SNAILMediatedEMT.FrontOncol.2020Jan9;9:1481.doi:10.3389/fonc.2019.01481.IF=5.716.JunweiZhao#,QinZhan,JunhanGuo,MinLiu,YetianRuan,TailinZhu,LingfeiHan,FangLi.PhylogenyandpolymorphismintheE6andE7ofhumanpapillomavirus:alpha-9(HPV16,31,33,52,58),alpha-5(HPV51),alpha-6(HPV53,66),alpha-7(HPV18,39,59,68)andalpha-10(HPV6,44)inwomenfromShanghai.InfectAgentCancer.2019Nov21;14:38.doi:10.1186/s13027-019-0250-9.IF=3.6917.JunweiZhao#,JiachengZhu,JunhanGuo,TailinZhu,JixingZhong,MinLiu,YetianRuan,ShujieLiao,FangLi.GeneticvariabilityandfunctionalimplicationofHPV16fromcervicalintraepithelialneoplasiainShanghaiwomen.JMedVirol.2020Mar;92(3):372-381.doi:10.1002/jmv.25618.IF=20.6918.ChaoLi#,YanfeiLi#,LanxiaSui,JianWang,FangLi,PhenyllacticacidpromotescellmigrationandinvasionincervicalcancerviaIKK/NF-κB-mediatedMMP-9activation.CancerCellInt.2019Sep23;19:241.doi:10.1186/s12935-019-0965-0.IF=6.4219.HuiyanHu#,JingjingZhao#,WenYu,JunweiZhao,ZheweiWang,LinJin,YunyunYu,LingfeiHan,LuWang,HuitingZhu,FangLi,HumanpapillomavirusDNA,HPVL1capsidproteinandp16INK4aproteinasmarkerstopredictcervicallesionprogression.ArchivesofGynecologyandObstetrics.2019Jan,299(1):141-149.IF=2.4920.JunweiZhao#,LuWang#,HuiLin,WenYu,XianghongXu,HuiyanHu,LaifangZhu,LingfeiHan,FangLi,AssociationofHLA-DRB1/DQB1polymorphismwithhigh-riskHPVinfectionandcervicalintraepithelialneoplasiawomenfromShanghai.InternationalJournalofClinicalandExperimentalPathology,2018.2.15,11(2):748-756.21.YahuiZhang#,LinWang#,XiangXu#,FangLi,QingshengWu,Combinedsystemsofdifferentantibioticswithnano-CuOagainstEscherichiacoliandthemechanismsinvolved.Nanomedicine(Lond),2018Feb;13(3):339-351.IF=6.0922.XiaojieHuang#,ChaoLi#,FangLi,JunweiZhao,XiaopingWan,KaiWang,Cervicovaginalmicrobiotacompositioncorrelateswiththeacquisitionofhigh-riskhumanpapillomavirustypes.InternationalJournalofCancer,2018Aug1,143(3):621-634.IF=7.3123.DongshengChen#,SanjieJiang,XiaoyanMa,FangLi,TFBSbank:aplatformtodissectthebigdataofprotein-DNAinteractioninhumanandmodelspecies.NucleicAcidsResearch,2017.1.4,45(D1):D151-D157.IF=19.624.XiaohuiZhou#,YanfengShi,LijieWang,MeiLiu,FangLi,DistributionCharacteristicsofHumanPapillomavirusInfection:AStudyBasedonDatafromPhysicalExamination.AsianPacificJournalofCancerPrevention,2017Jul27,18(7):1875-1879.25.JunweiZhao#,FangFang#,YiGuo,TailinZhu,YunyunYu,FanfeiKong,LingfeiHan,DongshengChen,FangLi,HPV16integrationprobablycontributestocervicaloncogenesisthroughinterruptingtumorsuppressorgenesandinducingchromosomeinstability.JournalofExperimental&ClinicalCancerResearch,2016.11.25,35(1):180-180.IF=12.6626.YunyunYu#,LingfeiHan#,WenYu,YankangDuan,ZheweiWang,HuiyanHu,JunweiZhao,SumanSingh,FanfeiKong,LinJin,JingSun,FangLi,HighriskfactorsassociatedwithHPVpersistenceafterloopelectrosurgicalexcisionprocedureinpatientswithintraepithelialneoplasia.InternationalJournalofClinicalandExperimentalPathology,2017,10(2):1817-1824.27.YiGuo#,JiachangHu,LipingZhu,JingSun,LongxuXie,FanfeiKong,LingfeiHan,FangLi,PhysicalStatusandVariantAnalysisofHumanPapillomavirus16inWomenfromShanghai.GynecologicandObstetricInvestigation,2016.01.01,81(1):61-70.IF=2.7228.SumanSingh#,QianZhou#,YunyunYu,XianghongXu,XiaojieHuang,JunweiZhao,LingfeiHan,KaiWang,JingSun,FangLi,DistributionofHPVgenotypesinShanghaiwomen.InternationalJournalofClinicalandExperimentalPathology,2015.01.01,8(9):11901-11908.29.LingfeiHan#,WeiWang#,JiahongLu#,FanfeiKong,GeMa,YipingZhu,DongZhao,JianlongZhu,WenShuai,QianZhou,PingChen,LeiYe,JieTao,SarfrazAhmad,FangLi,JingSun,AAV-sBTLAfacilitatesHSP70vaccine-triggeredprophylacticantitumorimmunityagainstamurinemelanomapulmonarymetastasismodelinvivo.CancerLetters,2014.11.28,354(2):398-406.IF=9.7530.FangLi#,YiGuo,LingfeiHan,YankangDuan,FangFang,SumeiNiu,QiujieBa,HuaishiZhu,FanfeiKong,ChaoLin,XuejunWen,Invitroandinvivogrowthinhibitionofdrug-resistantovariancarcinomacellsusingacombinationofcisplatinandaTRAIL-encodingretrovirus.OncologyLetters,2012.12.01,4(6):1254-1258.IF=3.1131.FangLi#,QiujieBa#,SumeiNiu,YiGuo,YankangDuan,PengZhao,ChaoLin,JingSun,In-situformingbiodegradableglycolchitosan-basedhydrogels:Synthesis,characterization,andchondrocyteculture.MaterialsScienceandEngineering:C,2012.10.1,32(7):2017-2025.IF=8.4532.FangLi#,JingSun,HuaishiZhu,XuejunWen,ChaoLin,DongluShi,Preparationandcharacterizationnovelpolymer-coatedmagneticnanoparticlesascarriersfordoxorubicin.ColloidsandSurfacesB:Biointerfaces,2011.11.1,88(1):58-62.IF=5.9933.XuSong#,FangLi#,JingweiMa,NengqinJia,JianmingXu,HebaiShen,Synthesisoffluorescentsilicananoparticlesandtheirapplicationsasfluorescenceprobes.JournalofFluorescence,2011.5.01,21(3):1205-1212.IF=2.5234.FangLi#,SumeiNiu,JingSun,HuaishiZhu,QiujieBa,YiGuo,DongluShi,EfficientInVitroTRAIL-GeneDeliveryinDrug-ResistantA2780/DDPOvarianCancerCellLineviaMagnetofection.JournalofNanomaterials,2011.01.01.IF=3.7935.FangLi#,PingpingSu#,ChaoLin,HongLi,JiajingCheng,DongluShi,Ribosomedisplayandselectionofhumananti-placentalgrowthfactorscFvderivedfromovariancancerpatients.ProteinandPeptideLetters,2010.5.01,17(5):585-590.IF=1.9236.Lin,Chao#,PengZhao#,FangLi,FangfangGuo,ZhuoquanLi,XuejunWen,Thermosensitiveinsitu-formingdextran-pluronichydrogelsthroughMichaeladdition.MaterialsScienceandEngineering:C,2010.01.01,30(8):1236-1244.IF=8.4537.FangLi#,JianingLi,XuejunWen,ShenghuZhou,XiaowenTong,PingpingSu,HongLi,DongluShi,Anti-tumoractivityofpaclitaxel-loadedchitosannanoparticles:Aninvitrostudy.MaterialsScienceandEngineering:C,2009.01.01,29(8):2392-2397.IF=8.4538.FangLi#,LiMeng#,HuiXing,JianfengZhou,ShixuanWang,LeiHuang,GangXu,HuaishiZhu,YunpingLu,DingMa,Essentialroleofc-Jun-NH2-terminalkinaseonsynergyinductionofapoptosisbyTRAILplusADMinADMresistantMCF-7/ADMcells.Apoptosis,2006.01.01,11:1239-1246.IF=5.9939.FangLi#,LiMeng#,JianfengZhou,HuiXing,ShixuanWang,GangXu,HuaishiZhu,BeibeiWang,GangChen,YunpingLu,DingMa,Reversingchemoresistanceincisplatin-resistanthumanovariancancercells:Aroleofc-JunNH(2)-terminalkinase1.BiochemicalandBiophysicalResearchCommunications,2005.10.01,335(4):1070-1077.IF=3.3240.LeiHuang#,QilinAo,QinghuaZhang,XiaokuiYang,HuiXing,FangLi,GangChen,JianfengZhou,ShixuanWang,GangXu,LiMeng,YunPingLu,DingMa,Hypoxiainducedpaclitaxelresistanceinhumanovariancancersviahypoxia-induciblefactor1alpha.JournalofCancerResearchandClinicalOncology,2010.3.01,136(3):447-456.IF=4.3241.胡家昌(#),李芳(通讯作者),高危型HPVDNA与宿主基因整合及致癌机理的相关研究进展,现代妇产科进展,2015.5.01,(05):384~386